Sandor Kantor, PhD
Bridging preclinical and clinical development with 20+ years of expertise in neurophysiological biomarkers, pharmaco-EEG, and CNS drug discovery.
About
I am a translational neuroscientist with over 20 years of experience bridging basic research and drug development. My career has spanned academic institutions including Harvard Medical School and the University of Cambridge, as well as leadership roles in the pharmaceutical industry.
As former Scientific Director at a multinational preclinical CRO, I led international teams delivering neurophysiological biomarker programmes for major pharmaceutical companies and innovative biotech firms. My expertise centres on EEG methodology, pharmaco-EEG profiling, and the design of translational studies that de-risk CNS drug development.
I hold a PhD in Clinical Medicine and have authored over 20 peer-reviewed publications in leading journals including Brain, Sleep, and Neurotherapeutics. My research has been supported by over £270,000 in competitive funding.
20+
Years of experience
20+
Publications
£270K+
Research funding
1500+
Citations
Therapeutic area expertise
Services
I offer specialist consulting services tailored to pharmaceutical companies, biotech firms, and academic research groups working in CNS drug discovery and neuroscience research.
Fast and detailed analysis of uploaded recordings, straightforward access to results and customised data presentation.
Visit Somnolect
Case studies
Real-world examples of neurophysiological studies conducted across species and therapeutic areas.
24-h wireless EEG/EMG recording in WKY rats after psilocybin
Kantor S, Higgins L, Upton N, Duxon M; SFN.org Neurosci Meeting Planner P711.05 (2021)
Pre-attentive auditory information processing after ketamine
Kantor S, Laursen B, Upton N, Bastlund JF; SFN.org Neurosci Meeting Planner 610.04 (2019)
Publications
A selection of peer-reviewed publications from over 20 papers spanning neurophysiology, sleep research, neurodegeneration, and CNS pharmacology.
Behavioural Brain Research 449, 114473
Neurotherapeutics 14, 1120–1133
Neuropharmacology 105, 298–307
Psychopharmacology 231, 593–601
Contact
Interested in discussing a project or exploring how I can support your research programme? I'd welcome the opportunity to hear about your needs.
Based in the United Kingdom. Available for remote consulting worldwide.
01 · Technical platforms & systems expertise
DSI PhysioTel implantable telemetry
TSE Neurologger
Staff training and technical workshops available on request.
02 · Study design & support
03 · Analysis platforms & methods
Kantor S et al. Behav. Brain Res. 449, 114473 (2023) · Sleep 36, 1129–38 (2013) · Sleep 32, 1127–34 (2009) · Brain 136, 2147–58 (2013)
04 · Bridging preclinical and clinical development
Changes in rodent sleep, EEG, and event-related potentials (ERP) directly mirror human responses to CNS-active compounds. This translational consistency makes EEG a powerful pharmacodynamic tool that enables quantitative, cross-species validation.
05 · Disease models & applications
Experience with psilocybin, ibogaine, and other neuroplastogens.
06 · Ongoing support services
Global CRO experience (Transpharmation Ltd): multi-site study coordination, regulatory standards compliance, IND-enabling study support, and a strong academic research foundation.
20+ peer-reviewed publications in high-impact journals including Brain, Sleep, and Neurotherapeutics.
